Feb 13, 2020 / 09:00AM GMT
Operator
Ladies and gentlemen, welcome to the Sobi presentation of the Q4 and full year 2019 results. (Operator Instructions)
I will now hand over to Guido Oelkers, CEO. Please go ahead.
Guido Oelkers - Swedish Orphan Biovitrum AB(publ)-CEO&President
Yes, good morning, everybody. It's really my pleasure to welcome you to our webcast on the Q4 results. And I think with this, we go straight into the brief. Forward-looking statement as per usual.
Today, I'm accompanied by our CFO, Henrik Stenqvist; and our Head of R&D, Milan Zdravkovic. And this has been -- 2019 has been a significant journey for the company. And before I get into the numbers, I think it's time just to quickly reflect what actually happened. We really grew now our Haemophilia business with the acquisition of Doptelet or broadened it into a Haematology franchise. We got our first launch experience with Gamifant during the year, and $56 million, I think, made our first mark. We had Synagis under -- as the first year -- in the first
Q4 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Feb 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers